US FDA Considers Newron ’s Re-Submitted NDA for Xadago to be a Complete, Class 2 Response to Complete Response Letter

MILAN--(BUSINESS WIRE)-- October 21, 2016 -- Newron Pharmaceuticals S.p.A. ( “Newron”) (NWRN.SW), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news